Pacira Biosciences (PCRX) reported preliminary 2024 revenue Friday of $701 million, up from $675 million a year earlier.
Analysts polled by FactSet expect $695.1 million.
The company also outlined a five-year strategy to expand its focus on musculoskeletal pain and related areas, aiming for growth by 2030.
The plan, called 5x30, includes treating more than 3 million patients annually, achieving double-digit annual revenue growth, increasing gross margins by 5 percentage points, advancing five new clinical programs and establishing five partnerships, Pacira said.
Shares of the company jumped 16% in recent Friday trading.
Price: 21.62, Change: +3.04, Percent Change: +16.36
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。